top of page
Sage Group News
Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol
Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company...
Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem
Glycostem Therapeutics B.V. (“Glycostem” or the “Company”). Glycostem is a cell therapy company focused on developing stem cell-derived...
SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics
Conceptomed, an innovative Norwegian based medtech company, has created SalivaPOD™ for easy-to-use saliva sample collection. SalivaPOD™...
Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China
Sage's very exciting Chinese client, Guangzhou Doublle Bio-Product Co., Ltd., will report the results of its Chinese Phase 3 study of its...
The Sage Group Invites You to a Webinar by Axiom Space on November 30, 2021at 11 AM Eastern Time
Innovative Biological R&D in Microgravity Environments A Free Webinar You Should Not Miss! We learned of Axiom Space (Axiom Space -...
The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug
New York and London, July 28, 2021 - The Sage Group has announced that it advised Cancer Prevention Pharmaceuticals, Inc. (CPP),...
Sage Represents medac GmbH in Deal for Commercialisation Agreement for Treosulfan in Canada
Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada...
bottom of page